Real life long-term efficacy and safety of ixekizumab in moderate-to-severe psoriasis: A 192 weeks multicentric retrospective study-IL PSO (Italian landscape psoriasis).
Malagoli P, Dapavo P, Pavia G, Amoruso F, Argenziano G, Bardazzi F, Burlando M, Carrera CG, Damiani G, Dini V, Girolomoni G, Guarneri C, Loconsole F, Narcisi A, Sampogna F, Travaglini M, Costanzo A.
Malagoli P, et al. Among authors: carrera cg.
Dermatol Ther. 2022 Aug;35(8):e15608. doi: 10.1111/dth.15608. Epub 2022 Jun 8.
Dermatol Ther. 2022.
PMID: 35638250